RachelWLinnemannMD

Pediatric Pulmonology • Atlanta, GA

Attending Physician, Children’s Healthcare of Atlanta Associate Professor, Emory University School of Medicine

Join to view full profile

Dr. Linnemann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Linnemann's full profile

Already have an account?

Office
1400 Tullie Rd NE
Fl 5
Atlanta, GA 30329
Phone+1 404-785-5437

Fax+1 404-785-9087

Education & Training

Massachusetts General HospitalFellowship, Pediatric Pulmonology, 2012 - 2015
Massachusetts General HospitalResidency, Pediatrics, 2009 - 2012
Yale School of MedicineClass of 2009

Certifications & Licensure

GA State Medical License 2015 - 2026
MA State Medical License 2011 - 2016
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Pulmonology

Clinical Trials

Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention Start of enrollment: 2021 Jun 25
Active, not recruiting
Not Applicable
Roles: Contact, Principal Investigator
Trikafta in Cystic Fibrosis Patients Start of enrollment: 2019 Sep 04
COMPLETED
PHASE2
Roles: Contact

Publications & Presentations

PubMed

3 citations
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 a...
Claire Keating, Lael M Yonker, François Vermeulen, Dario Prais, Rachel W Linnemann
The Lancet. Respiratory Medicine. 2025-03-01
2 citations
Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRin the USA: a prospective, multicentre, open-label, single-arm trial.
George M Solomon, Rachel W Linnemann, Rachel Rich, Ashleigh Streby, Brian Buehler
The Lancet. Respiratory Medicine. 2024-12-01
3 citations
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.
Nicole Mayer-Hamblett, Alex H Gifford, Margaret Kloster, Renee Russell, Andrew T Braun
Annals of the American Thoracic Society. 2024-11-01

Press Mentions

Children’s Healthcare of Atlanta and Emory University Cystic Fibrosis Care Center Receives Cystic Fibrosis Foundation’s 2024 Outstanding Care Center Partnership AwardNovember 26th, 2024
Transition Planning for Chronic Illnesses in the Time of COVID-19December 3rd, 2020